Clinical trial
A Phase Il, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Immunogenicity and Safety of a Therapeutic, Recombinant, Biologically Active HIV-1 Tat Protein Vaccine in HIV-Infected, Anti-Tat Negative, ARV-Treated Adult Volunteers
NCT01513135 is registered in ClinicalTrials.gov with Barbara Ensoli, MD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Il, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Immunogenicity and Safety of a Therapeutic, Recombinant, Biologically Active HIV-1 Tat Protein Vaccine in HIV-Infected, Anti-Tat Negative, ARV-Treated Adult Volunteers
- Lead sponsor
- Barbara Ensoli, MD
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2012
- Completion date
- July 31, 2014
- Enrollment
- 200 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.